Hengrui Pharma(SH:600276) Xin Hua Ri Bao·2025-08-05 23:41Group 1 - Jiangsu province approved 14 innovative drugs for market launch in the first seven months of this year, surpassing last year's total of 13, accounting for nearly 30% of the 49 innovative drugs approved nationwide [1] - The innovative drugs target diseases such as tumors, spondyloarthritis, and influenza, with a notable drug being the first anti-angiogenic drug for "platinum-resistant" ovarian cancer developed by Jiangsu Shensheng Biopharmaceutical Co., Ltd [1] - Jiangsu's pharmaceutical industry is supported by nearly 3,000 high-tech enterprises in the biopharmaceutical sector, with 16 companies ranked among the top 100 in China's pharmaceutical industry by main business revenue for 2024, leading the nation [2] Group 2 - Jiangsu province is constructing seven national key laboratories in the biopharmaceutical field and has established the first national technology innovation center for biopharmaceutical technology [2] - Jiangsu Hengrui Medicine Co., Ltd. has submitted applications for new treatments for active ankylosing spondylitis and recurrent or metastatic cervical cancer, reflecting the company's commitment to innovation with a research and development investment of 29.4% of sales revenue last year [2] - The province is optimizing drug review and approval processes, exemplified by the segmented production model for the antibody-drug conjugate developed by Suzhou Shengdiya Biopharmaceutical Co., Ltd., which enhances resource allocation and collaboration within the industry [3]